Delivery Order SPE2DR25D2206-SPE2DR26F9BA2
- Not listed
- The Defense Logistics Agency awarded a $9.4K delivery order to AmerisourceBergen Drug Corp on April 25, 2025, for the supply of Prevymis 480 mg tablets in quantities of seven units. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procurement procedures. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of May 16, 2025. This delivery order is issued as...
- The Defense Logistics Agency awarded a $4,719.34 delivery order to AmerisourceBergen Drug Corp for Prevymis 480 mg tablets (7-count package) on August 22, 2025, with completion scheduled for September 15, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and is being fulfilled from the vendor's location in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Prevymis 480 mg tablets (7-count packaging) with a ceiling value of $4,719.34. This competitively awarded, non-set-aside contract is structured as a firm fixed-price delivery order and is scheduled for ultimate completion by August 29, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a $4,719.34 firm fixed price delivery order to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of Prevymis 480 mg tablets in quantities of seven per unit. This non-set-aside competitive award will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania, with a completion date of November 21, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor,...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Prevymis 480 mg tablets (7-count packages) valued at $4,719.34. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 23, 2025, with performance at the contractor's corporate headquarters in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $4,745.80 to AmerisourceBergen Drug Corp for Prevymis 480 mg tablets (14-count) on August 26, 2025, with completion scheduled for September 17, 2025. This non-set-aside, firm fixed-price contract represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Prevymis 480 mg tablets in a quantity of seven units, with a total ceiling value of $4,719.34. This firm fixed-price delivery order is scheduled for completion by October 2, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $9,438.70 to AmerisourceBergen Drug Corp for the supply of Prevymis 480 mg tablets (quantity 7) with a completion date of October 8, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of the company's role as a critical pharmaceutical supplier to the federal government. The order will be fulfilled from AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Prevymis 480 mg tablets in seven-tablet packages, with a contract ceiling value of $9,438.70 and a firm fixed price structure. This non-set-aside delivery order is scheduled for completion by September 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's ongoing...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $9,438.68 for PREVYMIS 480 mg tablets (7-count units) with an ultimate completion date of November 6, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The work will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- SPE2DR25D2206Indefinite Delivery Contract
- SPE2DR25D2206-SPE2DR26F9BA2Delivery Order
The Defense Logistics Agency awarded a $14.9K delivery order to AmerisourceBergen Drug Corp on November 10, 2025, for the supply of Prevymis (480 mg tablets, quantity 7) with a completion date of December 3, 2025. This competitively awarded, non-set-aside contract reflects firm fixed pricing terms and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.9 million through December 2026, which serves as a comprehensive global pharmaceutical support mechanism for military healthcare systems. Prevymis, an antiviral medication, aligns with the broader medical supply portfolio that AmerisourceBergen delivers to support Defense Health Agency and other federal healthcare systems. The award underscores the company's established role as a critical pharmaceutical distributor within the federal medical supply chain, fulfilling specialized medication requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.9k | 11/10/25 |